While Lilly and Novo are still the only two companies with approved weight-loss drugs on sale in the U.S., others are coming for a share of the growing sector.

The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after ...

LILLY BOROUGH, Pa. — A man in his 70s was killed in a single-vehicle crash early this morning at the intersection of Evergreen Street and Main Street in Lilly B ...

Lilly hit as PBM drops Zepbound, but retains Wegovy Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

If you're looking for a top healthcare stock to buy that has much more upside in GLP-1, then going with Eli Lilly or Novo Nordisk can make much more sense at this stage.

Sascha Berger, private biopharmaceutical investor; Shannon Eaker, CTO of Xcellbio; Edwin Stone, CEO of Cellular Origins; and Bryce Sady, VP of Product Development at PSL Group go behind the headlines ...

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed ...

Explore 5 Nigerian-owned lipstick brands with long-lasting formulas, bold shades for dark skin, and affordable prices you can shop online.

The 5 best lipstick perfumes are so much more appealing than they sound. These are our Shopping Editor's favourite complex and distinctive scents.

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s nonprofit acquires 23andMe.